Close Menu

Alnylam Pharmaceuticals and Regulus Therapeutics, a joint venture between Alnylam and Isis Pharmaceuticals, said this week that the US Patent and Trademark Office has issued a notice of allowance for a patent application covering several chemical classes of antisense-based microRNA antagonists.

The application, No. 20060058266, is entitled "Chemically modified oligonucleotides," and claims "composition and methods for making and using chemically modified oligonucleotide agents for inhibiting gene expression," according to its abstract.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Nature News reports on how meeting cancellations and related costs are affecting scientific societies.

In a new ruling, Canada's Supreme Court upheld the country's genetic non-discrimination law, the Canadian Press reports.

COVID-19 vaccine developers aim to avoid a complication that has affected efforts to develop vaccines for other diseases, the Wall Street Journal reports.

In PLOS this week: analysis of insertions throughout Shigella genomes, antigen production in malaria parasites, and more.